EUCTR2009-012445-35-DK
Active, not recruiting
Not Applicable
Aldosterone receptor blockade in patients with chronic kidney disease.Influence on arterial stiffness and kidney function. - ALBLOCK-2
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic kidney disease, stages 3 and 4.
- Sponsor
- Herlev Hospital
- Enrollment
- 80
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patienten kan indgå i studiet, såfremt følgende er opfyldt:
- •\- Alder mellem 18 og 80 år
- •\- Der er afgivet frivilligt informeret samtykke
- •\- 15 ml/min/1,73 m2 \= estimeret GFR \< 60 ml/min/1,73m2
- •\- blodtryk over eller lig med 130/80 mmHg eller behandling med anti\-hypertensiva
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
Exclusion Criteria
- •Patienten kan ikke indgå i studiet hvis
- •\- p\-kalium \> 5,0 mM
- •\- er allergi over for indholdsstoffet
- •\- er i behandling med spironolakton
- •\- er i behandling med kraftige CYP3A4\-hæmmere (itraconazol, ketoconazol, ritonavir, nelfinavir, clarithromycin, telithromycin, nefazodon)
- •\- er i behandling med lithium, ciclosporin, tacrolimus, prednisolon eller anden immunsuppressiv behandling
- •\- har arvelig galactoseintolerans, lactasemangel, glucose/galactosemalabsorption
- •\- er gravid eller ammende
- •\- er kvinde i den fertile alder og ikke anvender sikker anti\-konception i form af p\-piller, spiral eller depotgestagen
- •\- demens eller anden psykisk tilstand, der umuliggør forståelse af undersøgelsesbetingelserne
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Establishing the benefits of a tablet commonly used to treat raised blood pressure in people with Chronic Kidney Disease stage 3b.We plan a large pragmatic trial to test the potential for spironolactone to to reduce overall cardiovascular events and death, to delay the decline in renal function, and to improve surrogate markers for vascular disease in people with stage 3b (eGFR 30-44 ml/min/1.73m2)Chronic Kidney Disease.MedDRA version: 15.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 15.1Level: PTClassification code 10018355Term: Glomerular filtration rateSystem Organ Class: 10022891 - InvestigationsMedDRA version: 15.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]EUCTR2012-002672-13-GBniversity of Oxford, Clinical Trials and Research Governance Office2,616
Completed
Not Applicable
Aldosterone blockade in children with chronic allograft nephropathyISRCTN19419571Sectorial Fund for Health Research (Fondo Sectorial de Investigación en Salud) (Mexico)62
Active, not recruiting
Phase 1
A randomised blinded placebo controlled trial of hydrocortisone in critically ill patients with septic shockEUCTR2012-003158-10-IEThe George Institute for Global Health3,800
Active, not recruiting
Phase 1
A randomised blinded placebo controlled trial of hydrocortisone in critically ill patients with septic shockEUCTR2012-003158-10-DKThe George Institute for Global Health3,800
Active, not recruiting
Not Applicable
A randomised blinded placebo controlled trial of hydrocortisone in critically ill patients with septic shockSeptic ShockMedDRA version: 16.1Level: PTClassification code 10040070Term: Septic shockSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2012-003158-10-GBThe George Institute for Global Health3,800